Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 02, 2017 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Announces Multiple Abstracts Related to Anti-TIGIT Program Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2017

REDWOOD CITY, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) will present new data related to its clinical and preclinical immuno-oncology and anti-cancer stem...
March 01, 2017 16:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals to Report Fourth Quarter and Year End Financial Results on March 8, 2017

REDWOOD CITY, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
February 13, 2017 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Enrolls First Patient in Phase 1b Clinical Trial of its Anti-DLL4/VEGF Bispecific Antibody in Patients with Platinum-Resistant Ovarian Cancer

REDWOOD CITY, Calif., Feb. 13, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and...
February 08, 2017 16:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals to Present at the BIO CEO and Investor and Leerink Global Healthcare Conferences

REDWOOD CITY, Calif., Feb. 08, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and...
January 20, 2017 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Initiates Enrollment of Phase 1b Clinical Trial of Brontictuzumab for the Treatment of Metastatic Colorectal Cancer Patients

REDWOOD CITY, Calif., Jan. 20, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and...
January 05, 2017 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Announces Year-End Cash Balance and 2017 Outlook

Enters 2017 with $184.6 Million in Cash Potential for Five Program Opt-ins Totaling Over $170M Anti-TIGIT (I/O#2) IND Filed REDWOOD CITY, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) -- OncoMed...
January 04, 2017 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Initiates Enrollment of Phase 1b Clinical Trial of Anti-DLL4/VEGF Bispecific Antibody as Second-line Treatment for Metastatic Colorectal Cancer Patients

REDWOOD CITY, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and...
December 05, 2016 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Announces Departure of Chief Medical Officer

REDWOOD CITY, Calif. , Dec. 05, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company focused on discovering and developing novel anti-cancer stem cell...
November 29, 2016 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Presents Initial First-in-Human Data for Anti-DLL4/VEGF Bispecific and Anti-RSPO3 at the 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

Partial Responses and Stable Disease Achieved with Bispecific as a Single-Agent Safety and Target Engagement Established for Anti-RSPO3 REDWOOD CITY, Calif., Nov. 29, 2016 (GLOBE NEWSWIRE) --...
November 22, 2016 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals to Present at the 28th Annual Piper Jaffray Healthcare Conference

REDWOOD CITY, Calif., Nov. 22, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right